Cell transplantation in the damaged adult brain.
Identifieur interne : 000725 ( PubMed/Checkpoint ); précédent : 000724; suivant : 000726Cell transplantation in the damaged adult brain.
Auteurs : M. Jaber [France] ; M. Benoit-Marand ; L. Prestoz ; A. GaillardSource :
- Revue neurologique [ 0035-3787 ] ; 2013.
English descriptors
- KwdEn :
- Adult, Animals, Behavior (physiology), Brain (pathology), Cell Transplantation (methods), Corpus Striatum (pathology), Corpus Striatum (transplantation), Humans, Nerve Degeneration (pathology), Nerve Degeneration (therapy), Nerve Net (pathology), Parkinson Disease (pathology), Parkinson Disease (therapy), Substantia Nigra (pathology), Substantia Nigra (transplantation).
- MESH :
- methods : Cell Transplantation.
- pathology : Brain, Corpus Striatum, Nerve Degeneration, Nerve Net, Parkinson Disease, Substantia Nigra.
- physiology : Behavior.
- therapy : Nerve Degeneration, Parkinson Disease.
- transplantation : Corpus Striatum, Substantia Nigra.
- Adult, Animals, Humans.
Abstract
Parkinson's disease (PD) is the most common movement disorder in Europe, affecting more than two million people between 50 and 70 years of age. The current therapeutic approaches are of symptomatic nature and fail to halt the progressive neurodegenerative course of the disease. The development of innovative and complementary approaches to promote cellular repair may pave the way for disease-modifying therapies which may lead to less suffering for the patients and their families and finally to more cost-effective therapies. To date, cell replacement trials in PD aiming at replacing lost dopamine neurons were mainly focused on placing the transplanted cells within the target site, the striatum, and not within the lesioned site, the substantia nigra (SN). This was based on the misconception that the adult brain constitutes a non-permissive barrier not allowing the outgrowth of long distance axons originating from transplanted embryonic neurons. A growing body of evidence is challenging this concept and proposing instead to place the graft within its ontogenic site. This has been performed in several lesional animal models for various traumatic or neurodegenerative pathologies of the brain. For instance, transplanted neurons within the lesioned motor cortex were shown to be able to send distant and appropriate projections to target areas including the spinal cord. Similarly, in an animal model of PD, mesencephalic embryonic cells transplanted within the lesioned SN send massive projections to the striatum and, to a lesser extent, the frontal cortex and the nucleus accumbens. This has lead to the proposal that homotopic transplantation may be an alternative in cell-based therapies as transplanted neurons can integrate within the host brain, send projections to target areas, restore the damaged circuitry, increase neurotransmitter levels and ameliorate behavior. We will discuss also the potential of replacing embryonic neuronal cells by stem cell derived neurons as the use of embryonic cells is not without an ethical and logistical burden; in this line many have thrived to derive neurons from embryonic stem cells (ESC) in order to use them for cell transplantation. These studies are already yielding important information for future approaches in the field of cell therapies in PD but also in other neurodegenerative disorders where cell transplantation therapy may be considered. While the field of cell replacement therapies has been recently called into question with contrasting results in transplanted PD patients, these new sets of findings are raising new hopes and opening new avenues in this rejuvenated field.
DOI: 10.1016/j.neurol.2013.07.026
PubMed: 24112517
Affiliations:
Links toward previous steps (curation, corpus...)
Links to Exploration step
pubmed:24112517Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Cell transplantation in the damaged adult brain.</title><author><name sortKey="Jaber, M" sort="Jaber, M" uniqKey="Jaber M" first="M" last="Jaber">M. Jaber</name><affiliation wicri:level="3"><nlm:affiliation>Inserm U1084, university of Poitiers, building B36, 1, rue Georges-Bonnet, BP 633, 86022 Poitiers cedex, France. Electronic address: mohamed.jaber@univ-poitiers.fr.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Inserm U1084, university of Poitiers, building B36, 1, rue Georges-Bonnet, BP 633, 86022 Poitiers cedex</wicri:regionArea><placeName><region type="region" nuts="2">Nouvelle-Aquitaine</region><region type="old region" nuts="2">Poitou-Charentes</region><settlement type="city">Poitiers</settlement></placeName></affiliation></author><author><name sortKey="Benoit Marand, M" sort="Benoit Marand, M" uniqKey="Benoit Marand M" first="M" last="Benoit-Marand">M. Benoit-Marand</name></author><author><name sortKey="Prestoz, L" sort="Prestoz, L" uniqKey="Prestoz L" first="L" last="Prestoz">L. Prestoz</name></author><author><name sortKey="Gaillard, A" sort="Gaillard, A" uniqKey="Gaillard A" first="A" last="Gaillard">A. Gaillard</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2013">2013</date><idno type="RBID">pubmed:24112517</idno><idno type="pmid">24112517</idno><idno type="doi">10.1016/j.neurol.2013.07.026</idno><idno type="wicri:Area/PubMed/Corpus">000672</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000672</idno><idno type="wicri:Area/PubMed/Curation">000644</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000644</idno><idno type="wicri:Area/PubMed/Checkpoint">000644</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">000644</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Cell transplantation in the damaged adult brain.</title><author><name sortKey="Jaber, M" sort="Jaber, M" uniqKey="Jaber M" first="M" last="Jaber">M. Jaber</name><affiliation wicri:level="3"><nlm:affiliation>Inserm U1084, university of Poitiers, building B36, 1, rue Georges-Bonnet, BP 633, 86022 Poitiers cedex, France. Electronic address: mohamed.jaber@univ-poitiers.fr.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Inserm U1084, university of Poitiers, building B36, 1, rue Georges-Bonnet, BP 633, 86022 Poitiers cedex</wicri:regionArea><placeName><region type="region" nuts="2">Nouvelle-Aquitaine</region><region type="old region" nuts="2">Poitou-Charentes</region><settlement type="city">Poitiers</settlement></placeName></affiliation></author><author><name sortKey="Benoit Marand, M" sort="Benoit Marand, M" uniqKey="Benoit Marand M" first="M" last="Benoit-Marand">M. Benoit-Marand</name></author><author><name sortKey="Prestoz, L" sort="Prestoz, L" uniqKey="Prestoz L" first="L" last="Prestoz">L. Prestoz</name></author><author><name sortKey="Gaillard, A" sort="Gaillard, A" uniqKey="Gaillard A" first="A" last="Gaillard">A. Gaillard</name></author></analytic><series><title level="j">Revue neurologique</title><idno type="ISSN">0035-3787</idno><imprint><date when="2013" type="published">2013</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adult</term><term>Animals</term><term>Behavior (physiology)</term><term>Brain (pathology)</term><term>Cell Transplantation (methods)</term><term>Corpus Striatum (pathology)</term><term>Corpus Striatum (transplantation)</term><term>Humans</term><term>Nerve Degeneration (pathology)</term><term>Nerve Degeneration (therapy)</term><term>Nerve Net (pathology)</term><term>Parkinson Disease (pathology)</term><term>Parkinson Disease (therapy)</term><term>Substantia Nigra (pathology)</term><term>Substantia Nigra (transplantation)</term></keywords><keywords scheme="MESH" qualifier="methods" xml:lang="en"><term>Cell Transplantation</term></keywords><keywords scheme="MESH" qualifier="pathology" xml:lang="en"><term>Brain</term><term>Corpus Striatum</term><term>Nerve Degeneration</term><term>Nerve Net</term><term>Parkinson Disease</term><term>Substantia Nigra</term></keywords><keywords scheme="MESH" qualifier="physiology" xml:lang="en"><term>Behavior</term></keywords><keywords scheme="MESH" qualifier="therapy" xml:lang="en"><term>Nerve Degeneration</term><term>Parkinson Disease</term></keywords><keywords scheme="MESH" qualifier="transplantation" xml:lang="en"><term>Corpus Striatum</term><term>Substantia Nigra</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Adult</term><term>Animals</term><term>Humans</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Parkinson's disease (PD) is the most common movement disorder in Europe, affecting more than two million people between 50 and 70 years of age. The current therapeutic approaches are of symptomatic nature and fail to halt the progressive neurodegenerative course of the disease. The development of innovative and complementary approaches to promote cellular repair may pave the way for disease-modifying therapies which may lead to less suffering for the patients and their families and finally to more cost-effective therapies. To date, cell replacement trials in PD aiming at replacing lost dopamine neurons were mainly focused on placing the transplanted cells within the target site, the striatum, and not within the lesioned site, the substantia nigra (SN). This was based on the misconception that the adult brain constitutes a non-permissive barrier not allowing the outgrowth of long distance axons originating from transplanted embryonic neurons. A growing body of evidence is challenging this concept and proposing instead to place the graft within its ontogenic site. This has been performed in several lesional animal models for various traumatic or neurodegenerative pathologies of the brain. For instance, transplanted neurons within the lesioned motor cortex were shown to be able to send distant and appropriate projections to target areas including the spinal cord. Similarly, in an animal model of PD, mesencephalic embryonic cells transplanted within the lesioned SN send massive projections to the striatum and, to a lesser extent, the frontal cortex and the nucleus accumbens. This has lead to the proposal that homotopic transplantation may be an alternative in cell-based therapies as transplanted neurons can integrate within the host brain, send projections to target areas, restore the damaged circuitry, increase neurotransmitter levels and ameliorate behavior. We will discuss also the potential of replacing embryonic neuronal cells by stem cell derived neurons as the use of embryonic cells is not without an ethical and logistical burden; in this line many have thrived to derive neurons from embryonic stem cells (ESC) in order to use them for cell transplantation. These studies are already yielding important information for future approaches in the field of cell therapies in PD but also in other neurodegenerative disorders where cell transplantation therapy may be considered. While the field of cell replacement therapies has been recently called into question with contrasting results in transplanted PD patients, these new sets of findings are raising new hopes and opening new avenues in this rejuvenated field.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">24112517</PMID><DateCreated><Year>2013</Year><Month>11</Month><Day>04</Day></DateCreated><DateCompleted><Year>2014</Year><Month>07</Month><Day>01</Day></DateCompleted><DateRevised><Year>2013</Year><Month>11</Month><Day>04</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Print">0035-3787</ISSN><JournalIssue CitedMedium="Internet"><Volume>169</Volume><Issue>11</Issue><PubDate><Year>2013</Year><Month>Nov</Month></PubDate></JournalIssue><Title>Revue neurologique</Title><ISOAbbreviation>Rev. Neurol. (Paris)</ISOAbbreviation></Journal><ArticleTitle>Cell transplantation in the damaged adult brain.</ArticleTitle><Pagination><MedlinePgn>838-43</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.neurol.2013.07.026</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0035-3787(13)00911-9</ELocationID><Abstract><AbstractText>Parkinson's disease (PD) is the most common movement disorder in Europe, affecting more than two million people between 50 and 70 years of age. The current therapeutic approaches are of symptomatic nature and fail to halt the progressive neurodegenerative course of the disease. The development of innovative and complementary approaches to promote cellular repair may pave the way for disease-modifying therapies which may lead to less suffering for the patients and their families and finally to more cost-effective therapies. To date, cell replacement trials in PD aiming at replacing lost dopamine neurons were mainly focused on placing the transplanted cells within the target site, the striatum, and not within the lesioned site, the substantia nigra (SN). This was based on the misconception that the adult brain constitutes a non-permissive barrier not allowing the outgrowth of long distance axons originating from transplanted embryonic neurons. A growing body of evidence is challenging this concept and proposing instead to place the graft within its ontogenic site. This has been performed in several lesional animal models for various traumatic or neurodegenerative pathologies of the brain. For instance, transplanted neurons within the lesioned motor cortex were shown to be able to send distant and appropriate projections to target areas including the spinal cord. Similarly, in an animal model of PD, mesencephalic embryonic cells transplanted within the lesioned SN send massive projections to the striatum and, to a lesser extent, the frontal cortex and the nucleus accumbens. This has lead to the proposal that homotopic transplantation may be an alternative in cell-based therapies as transplanted neurons can integrate within the host brain, send projections to target areas, restore the damaged circuitry, increase neurotransmitter levels and ameliorate behavior. We will discuss also the potential of replacing embryonic neuronal cells by stem cell derived neurons as the use of embryonic cells is not without an ethical and logistical burden; in this line many have thrived to derive neurons from embryonic stem cells (ESC) in order to use them for cell transplantation. These studies are already yielding important information for future approaches in the field of cell therapies in PD but also in other neurodegenerative disorders where cell transplantation therapy may be considered. While the field of cell replacement therapies has been recently called into question with contrasting results in transplanted PD patients, these new sets of findings are raising new hopes and opening new avenues in this rejuvenated field.</AbstractText><CopyrightInformation>Copyright © 2013 Elsevier Masson SAS. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Jaber</LastName><ForeName>M</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Inserm U1084, university of Poitiers, building B36, 1, rue Georges-Bonnet, BP 633, 86022 Poitiers cedex, France. Electronic address: mohamed.jaber@univ-poitiers.fr.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Benoit-Marand</LastName><ForeName>M</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Prestoz</LastName><ForeName>L</ForeName><Initials>L</Initials></Author><Author ValidYN="Y"><LastName>Gaillard</LastName><ForeName>A</ForeName><Initials>A</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2013</Year><Month>10</Month><Day>07</Day></ArticleDate></Article><MedlineJournalInfo><Country>France</Country><MedlineTA>Rev Neurol (Paris)</MedlineTA><NlmUniqueID>2984779R</NlmUniqueID><ISSNLinking>0035-3787</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001519" MajorTopicYN="N">Behavior</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017690" MajorTopicYN="N">Cell Transplantation</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003342" MajorTopicYN="N">Corpus Striatum</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000637" MajorTopicYN="N">transplantation</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009410" MajorTopicYN="N">Nerve Degeneration</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009415" MajorTopicYN="N">Nerve Net</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010300" MajorTopicYN="N">Parkinson Disease</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013378" MajorTopicYN="N">Substantia Nigra</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000637" MajorTopicYN="N">transplantation</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Cellules souches embryonnaires</Keyword><Keyword MajorTopicYN="N">Cellules souches neuronales</Keyword><Keyword MajorTopicYN="N">Dopamine</Keyword><Keyword MajorTopicYN="N">Embryonic stem cells</Keyword><Keyword MajorTopicYN="N">Neural stem cells</Keyword><Keyword MajorTopicYN="N">Neurodegeneration</Keyword><Keyword MajorTopicYN="N">Neurodégénerescence</Keyword><Keyword MajorTopicYN="N">Striatum</Keyword><Keyword MajorTopicYN="N">Substance noire</Keyword><Keyword MajorTopicYN="N">Substantia nigra</Keyword><Keyword MajorTopicYN="N">striatum</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2013</Year><Month>05</Month><Day>02</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2013</Year><Month>07</Month><Day>04</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2013</Year><Month>07</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2013</Year><Month>10</Month><Day>12</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2013</Year><Month>10</Month><Day>12</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2014</Year><Month>7</Month><Day>2</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">24112517</ArticleId><ArticleId IdType="pii">S0035-3787(13)00911-9</ArticleId><ArticleId IdType="doi">10.1016/j.neurol.2013.07.026</ArticleId></ArticleIdList></PubmedData></pubmed><affiliations><list><country><li>France</li></country><region><li>Nouvelle-Aquitaine</li><li>Poitou-Charentes</li></region><settlement><li>Poitiers</li></settlement></list><tree><noCountry><name sortKey="Benoit Marand, M" sort="Benoit Marand, M" uniqKey="Benoit Marand M" first="M" last="Benoit-Marand">M. Benoit-Marand</name><name sortKey="Gaillard, A" sort="Gaillard, A" uniqKey="Gaillard A" first="A" last="Gaillard">A. Gaillard</name><name sortKey="Prestoz, L" sort="Prestoz, L" uniqKey="Prestoz L" first="L" last="Prestoz">L. Prestoz</name></noCountry><country name="France"><region name="Nouvelle-Aquitaine"><name sortKey="Jaber, M" sort="Jaber, M" uniqKey="Jaber M" first="M" last="Jaber">M. Jaber</name></region></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonFranceV1/Data/PubMed/Checkpoint
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000725 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/biblio.hfd -nk 000725 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= ParkinsonFranceV1
|flux= PubMed
|étape= Checkpoint
|type= RBID
|clé= pubmed:24112517
|texte= Cell transplantation in the damaged adult brain.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/RBID.i -Sk "pubmed:24112517" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Checkpoint/biblio.hfd \
| NlmPubMed2Wicri -a ParkinsonFranceV1
| This area was generated with Dilib version V0.6.29. |  |